{
    "root": "f492c348-c7b8-4004-847c-c023a10fbe47",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Loxapine",
    "value": "20250309",
    "ingredients": [
        {
            "name": "LOXAPINE SUCCINATE",
            "code": "X59SG0MRYU",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6549"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16134"
        },
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "BENZYL ALCOHOL",
            "code": "LKG8494WBH",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17987"
        },
        {
            "name": "BUTYLPARABEN",
            "code": "3QPI1U3FV8",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_88542"
        },
        {
            "name": "EDETATE CALCIUM DISODIUM",
            "code": "25IH6R4SGF",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14598"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "METHYLPARABEN",
            "code": "A2I8C7HI9T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31835"
        },
        {
            "name": "POLACRILIN POTASSIUM",
            "code": "0BZ5A00FQU"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32035"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "PROPYLPARABEN",
            "code": "Z8IX2SC1OH",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32063"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "SODIUM PROPIONATE",
            "code": "DK6Y9P42IN",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_132106"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "FERROSOFERRIC PHOSPHATE",
            "code": "91GQH8I5F7",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_26020"
        }
    ],
    "indications": {
        "text": "loxapine capsules indicated treatment schizophrenia . efficacy loxapine schizophrenia established enrolled newly hospitalized chronically hospitalized acutely ill schizophrenic patients subjects .",
        "doid_entities": [
            {
                "text": "schizophrenia (DOID:5419)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5419"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "loxapine capsules administered , usually divided doses , two four times day . daily ( terms base equivalents ) adjusted individual patient \u2019 needs assessed severity symptoms previous history response antipsychotic drugs .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "loxapine capsules , usp available following strengths : loxapine succinate , usp 6.8 mg equivalent 5 mg loxapine , black ink , hard shell , opaque , white body cap , printed \u201c watson 369 \u201d one half \u201c 5 mg \u201d , supplied bottles 100 ( ndc 0591-0369-01 ) . loxapine succinate , usp 13.6 mg equivalent 10 mg loxapine , black ink , hard shell , opaque , white body yellow cap , printed \u201c watson 370 \u201d one half \u201c 10 mg \u201d , supplied bottles 100 ( ndc 0591-0370-01 ) . loxapine succinate , usp 34.0 mg equivalent 25 mg loxapine , black ink , hard shell , opaque , white body green cap , printed \u201c watson 371 \u201d one half \u201c 25 mg \u201d , supplied bottles 100 ( ndc 0591-0371-01 ) . loxapine succinate , usp 68.1 mg equivalent 50 mg loxapine , black ink , hard shell , opaque , white body blue cap , printed \u201c watson 372 \u201d one half \u201c 50 mg \u201d , supplied bottles 100 ( ndc 0591-0372-01 ) . store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] . dispense tight , child-resistant container . manufactured india : watson pharma private limited verna , salcette goa 403 722 india manufactured : teva pharmaceuticals parsippany , nj 07054 rev . b 3/2025",
    "adverseReactions": "loxapine contraindicated comatose severe drug-induced depressed states ( alcohol , barbiturates , narcotics , etc . ) . loxapine contraindicated individuals known hypersensitivity dibenzoxazepines .",
    "indications_original": "Loxapine capsules are indicated for the treatment of schizophrenia. The efficacy of loxapine in schizophrenia was established in clinical studies which enrolled newly hospitalized and chronically hospitalized acutely ill schizophrenic patients as subjects.",
    "contraindications_original": "Loxapine capsules are administered, usually in divided doses, two to four times a day. Daily dosage (in terms of base equivalents) should be adjusted to the individual patient\u2019s needs as assessed by the severity of symptoms and previous history of response to antipsychotic drugs.",
    "warningsAndPrecautions_original": "Loxapine capsules, USP are available in the following strengths:\n                  Loxapine\u00a0succinate, USP 6.8 mg equivalent to 5 mg loxapine, black ink, hard shell, opaque, with a white body and cap, printed with \u201cWatson 369\u201d\u00a0on one half and \u201c5 mg\u201d\u00a0on the other, are supplied in bottles of 100 (NDC 0591-0369-01).\n                  Loxapine\u00a0succinate, USP 13.6 mg equivalent to 10 mg loxapine, black ink, hard shell, opaque, with a white body and yellow cap, printed with  \u201cWatson 370\u201d\u00a0on one half and  \u201c10 mg\u201d\u00a0on the other, are supplied in bottles of 100 (NDC 0591-0370-01).\n                  Loxapine\u00a0succinate, USP 34.0 mg equivalent to 25 mg loxapine, black ink, hard shell, opaque, with a white body and green cap, printed with \u201cWatson 371\u201d\u00a0on one half and \u201c25 mg\u201d\u00a0on the other, are supplied in bottles of 100 (NDC 0591-0371-01).\n                  Loxapine\u00a0succinate, USP 68.1 mg equivalent to 50 mg loxapine, black ink, hard shell, opaque, with a white body and blue cap, printed with \u201cWatson 372\u201d\u00a0on one half and \u201c50 mg\u201d\u00a0on the other, are supplied in bottles of 100 (NDC 0591-0372-01).\n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [See USP Controlled Room Temperature]. Dispense in a tight, child-resistant container.\n                  Manufactured In India By:\n                     Watson Pharma Private Limited\n                     \nVerna, Salcette Goa 403 722 INDIA\n                  Manufactured For:\n                     Teva Pharmaceuticals\n                     \nParsippany, NJ 07054\n                  Rev. B 3/2025",
    "adverseReactions_original": "Loxapine is contraindicated in comatose or severe drug-induced depressed states (alcohol, barbiturates, narcotics, etc.).\n                  Loxapine is contraindicated in individuals with known hypersensitivity to dibenzoxazepines.",
    "drug": [
        {
            "name": "Loxapine",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50841"
        }
    ]
}